3.190EUR+3.91%Mkt Cap: 65.25M $P/E: —Today
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in p…